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Aim: N-3 fatty acids, especially eicosapentaenoic acid (EPA), may possess anticachectic properties. This
trial compared a protein and energy dense supplement enriched with n-3 fatty acids and antioxidants
(experimental: E) with an isocaloric isonitrogenous control supplement (C) for their effects on weight, lean
body mass (LBM), dietary intake, and quality of life in cachectic patients with advanced pancreatic cancer.
Methods: A total of 200 patients (95 E; 105 C) were randomised to consume two cans/day of the E or C
supplement (480 ml, 620 kcal, 32 g protein¡ 2.2 g EPA) for eight weeks in a multicentre, randomised,
double blind trial.
Results: At enrolment, patients’ mean rate of weight loss was 3.3 kg/month. Intake of the supplements (E
or C) was below the recommended dose (2 cans/day) and averaged 1.4 cans/day. Over eight weeks,
patients in both groups stopped losing weight (Dweight E: 20.25 kg/month versus C: 20.37 kg/month;
p = 0.74) and LBM (DLBM E: +0.27 kg/month versus C: +0.12 kg/month; p = 0.88) to an equal degree
(change from baseline E and C, p,0.001). In view of evident non-compliance in both E and C groups,
correlation analyses were undertaken to examine for potential dose-response relationships. E patients
demonstrated significant correlations between their supplement intake and weight gain (r = 0.50,
p,0.001) and increase in LBM (r = 0.33, p = 0.036). Such correlations were not statistically significant in
C patients. The relationship of supplement intake with change in LBM was significantly different between E
and C patients (p = 0.043). Increased plasma EPA levels in the E group were associated with weight and
LBM gain (r = 0.50, p,0.001; r = 0.51, p = 0.001). Weight gain was associated with improved quality of
life (p,0.01) only in the E group.
Conclusion: Intention to treat group comparisons indicated that at the mean dose taken, enrichment with
n-3 fatty acids did not provide a therapeutic advantage and that both supplements were equally effective in
arresting weight loss. Post hoc dose-response analysis suggests that if taken in sufficient quantity, only the
n-3 fatty acid enriched energy and protein dense supplement results in net gain of weight, lean tissue, and
improved quality of life. Further trials are required to examine the potential role of n-3 enriched
supplements in the treatment of cancer cachexia.
T
he complex syndrome of cancer cachexia is a major
contributor to the morbidity and mortality of patients
with advanced malignancy.1 2 Causative factors include
metabolic alterations that result in hypermetabolism and
anorexia leading to reduced food intake. Previous studies
using conventional nutritional support have suggested there
is a partial block to the accretion of lean tissue in cancer
patients.3 Moreover, oral supplementation trials have failed
to show weight gain compared with controls.4 5 Such data
would tend to confirm the view that although food intake
needs to be increased in the cachectic cancer patient, gain in
lean tissue mass is difficult to achieve unless the underlying
metabolic abnormalities are corrected. The mediators respon-
sible for these changes are thought to be both tumour and
host derived and include proinflammatory cytokines, the
neuroendocrine system, and certain tumour specific factors
such as proteolysis inducing factor (PIF).6 7
Eicosapentaenoic acid (EPA), an n-3 fatty acid, has been
shown to have antitumour and anticachectic effects in the
murine MAC-16 colon adenocarcinoma model.8 In this
model, the effects of EPA have been related to inhibition of
PIF induced upregulation of key regulatory components of
the ubiquitin-proteasome proteolytic pathway.9 Administra-
tion of n-3 fatty acid or high purity EPA capsules has been
associated with weight stabilisation in weight losing patients
with advanced pancreatic cancer.10 11 These benefits may be
related to the effect of EPA on PIF but might also be related
to downregulation of proinflammatory cytokine produc-
tion.12 13 Whatever the mechanism, to improve functional
ability and hence quality of life, patients need not only to
become weight stable but to regain the lean tissue lost in the
cachectic process. Additional protein and energy are required
for lean tissue synthesis; hence the rationale for incor-
porating EPA as part of a high protein high energy oral
supplement. Furthermore, including specific antioxidants
may enhance the effect by protecting the unsaturated n-3
fatty acids in the supplement.14 In an open label trial,
consumption of two cans per day of such an oral supplement
resulted in a median weight gain of 1 kg at three weeks and
2 kg at seven weeks in weight losing patients with pancreatic
cancer (n = 20). Approximately 95% of the weight gain was
lean body mass (LBM).15
The aim of the present study was to compare the effect of
the same n-3 fatty acid and antioxidant enriched supplement
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations: EPA, eicosapentaenoic acid; PIF, proteolysis inducing
factor; LBM, lean body mass; TBW, total body water
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(experimental: E) with an isocaloric isonitrogenous supple-
ment (control: C) on weight, body composition, dietary
intake, and quality of life in weight losing pancreatic cancer
patients. The hypothesis was that n-3 fatty acids would
modulate metabolic abnormalities and thus promote anabo-
lism in patients with cachexia. Addition of protein and
energy would provide the elements necessary for the net gain
of weight and lean tissue.
PATIENTS AND METHODS
Patients
Patients with unresectable pancreatic cancer were selected
specifically for this study as these patients usually experience
severe progressive weight loss. Patients with histologically
proven or a firm radiological or operative diagnosis of
pancreatic cancer were included if they had lost more than
5% of their pre-illness stable weight over the previous six
months, had a Karnofsky performance score of 60 or more,
and had a life expectancy greater than two months. Patients
were excluded if they had undergone surgery, endoscopic
stenting, radiotherapy, or chemotherapy during the previous
four weeks; had other active medical conditions (major
gastrointestinal disease, chronic renal failure, uncontrolled
diabetes, and human immunodeficiency virus); a body mass
index greater than 30 kg/m2; or received medication which
could profoundly modulate metabolism or weight, in
particular, the use of fish oil or n-3 fatty acid preparations
exceeding 200 mg/day EPA, or one capsule of fish oil/day
within the previous 90 days. At the time of enrolment, no
patient had gross ascites or oedema, jaundice, pyrexia, severe
anaemia, or clinical or radiological evidence of infection. A
small number (n = 8) were receiving long term low dose
steroids for chronic benign conditions (for example, asthma).
None was taking steroids at doses above that for physio-
logical replacement. Pancreatic enzyme supplements were
administered if patients had or developed clinical evidence of
steatorrhoea. The ethics committees for human research of
the participating centres approved the protocol, and written
informed consent was obtained from all patients. Procedures
followed were in accordance with International Committee
for Harmonization, Good Clinical Practices and the Helsinki
Declaration.
Study design
The study was an international, multicentre, randomised,
double blind trial and was conducted between 27 January
1999 and 1 January 2001. Stratification was applied for the
12 participating centres and histological confirmation of
pancreatic cancer. The 12 participating centres were: Royal
Infirmary of Edinburgh, Edinburgh, UK; University Hospital
of Maastricht, Maastricht, the Netherlands; Centre
Hospilalier de l’Universite de Montreal (CHUM), Montreal,
Canada; Academisch Medisch Centrum, Amsterdam, the
Netherlands; Istituto Nazionale per la Ricerca sul Cancro,
Genoa, Italy; Universite Libre de Bruxelles Erasme, Brussels,
Belgium; The Wesley Hospital, Brisbane, Australia; Princess
Alexandra Hospital, Brisbane, Australia; Manchester Royal
Infirmary, Manchester, UK; Russells Hall Hospital, Dudley,
UK; Hammersmith Hospital, London, UK; and the General
Infirmary at Leeds, Leeds, UK. Patients were randomised at
enrolment in permutation blocks of two using a sequential
series of numbered sealed envelopes containing computer
generated random assignments. A copy of the randomisation
sequence was kept in a locked cabinet apart from the study
personnel. Randomisation envelopes were opened by a third
party who shipped the product directly to the patients’
homes. Patients, investigators, and study personnel were
blinded to the treatment group allocation. Study products
were packaged identically and not distinguishable from each
other. A sample size of 68 patients was calculated to detect a
difference in body weight of 1.6 kg (that is, an effect size of
0.8) between groups with a significance level of 0.05 and a
power of 0.9. Statistical power was based on changes in
weight from the pilot study data.15 Sample size was inflated
to 80 patients due to anticipating smaller effect size in other
measures (that is, quality of life). Therefore, 200 patients
were required to be enrolled in the study to obtain a
minimum of 80 patients, based on an anticipated 60%
attrition rate.
Patients were asked to consume two cans per day of either
a specially designed n-3 fatty acid and antioxidant enriched
oral supplement (E) or the identical supplement without n-3
fatty acids and enhanced antioxidants (C) for an eight week
period. Compliance was evaluated using the supplement
consumption records kept daily by patients and after the
blind was broken by measurement of plasma phospholipid
EPA levels.
Both oral supplements were provided by Ross Products
Division, Abbott Laboratories (Columbus, Ohio, USA) and
were ready to use, energy dense, high protein, low fat
formulations intended to act as a supplement to the patient’s
usual diet. Each 237 ml can provided 310 kcal, 16 g protein,
6 g fat, with or without 1.1 g of the n-3 fatty acid EPA, and
enriched antioxidants sufficient to protect the polyunsatu-
rated fatty acids from peroxidation (2524 IU vitamin A, 75 IU
vitamin E, 105 mg vitamin C, and 17.5 mg selenium). The
complete composition has been described by Barber and
colleagues.15 Patients were assessed for weight, body compo-
sition, dietary intake, and quality of life at baseline, and at
four and eight weeks.
Weight and body composition
At the initial assessment, height, pre-illness stable weight,
and duration of weight loss were self reported. Patients were
weighed without shoes and wearing light clothing on spring
balance scales (Tanita Solar Powered Scale Model 1618,
Tanita, Uxbridge, Middlesex, UK). The same scales were used
for consecutive visits.
Body composition was assessed using a Xitron Hydra
multiple frequency bioelectrical impedance analyser (Xitron
Technologies, San Diego, California, USA), as described
previously.16 Resistance was measured at 5 kHz and
200 kHz. Total body water (TBW) was derived using
equations validated in surgical patients.16 LBM was calculated
from TBW assuming that lean tissue contains 73% water.17
Pre-illness LBM was estimated from pre-illness body weight
using predictive equations based on height and weight for
TBW.18
Dietary intake
Three day diet diaries completed prior to assessments at
baseline (week 0), and weeks 4 and 8 were used to assess the
patients’ dietary intakes. Diet diaries have been shown to
reflect usual dietary intake.19 20 One weekend day and two
weekdays were used to account for potential day of the week
effects on dietary intake.20 A dietitian instructed patients on
how to record food and beverage intake. Mean total energy
and macronutrient intakes were calculated using country
specific computerised dietary analysis packages. Patients
were also asked to record the number of cans of supplement,
or parts thereof, consumed each day. Total dietary intake was
calculated by adding oral supplement consumption to
spontaneous food intake.
Plasma fatty acid analysis
Analysis of EPA in patients’ plasma phospholipids before
study commencement and at four and eight weeks was
performed by gas chromatography, as described previously.10
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A plasma EPA level of 1.6% is approximately the 90th
percentile in free living pancreatic cancer patients,15 21 and
this was used as the upper limit of the normal range.
Quality of life assessment
Quality of life was measured at baseline, and at four and
eight weeks using two self administered questionnaires: (1)
EuroQol EQ-5D, a generic quality of life measure that
provides a single index score (EQ-5Dindex) and the respon-
dent’s assessment of his or her overall health state (EQ-
5Dvas)
22; and (2) the European Organization for Research and
Treatment of Cancer (EORTC) QLQ-C30, a multidimensional
cancer specific measure that includes a global health status
and quality of life scale, function, and symptom scales.23 The
physical performance and global health status components
alone were used in the statistical analysis. Karnofsky
performance score was also documented.
Statistical analysis
The primary analysis was conducted on an intent to treat
basis, and therefore available data from all patients entered
into the study were used. Study groups were assessed for
comparability at study entry. For continuous variables,
changes were calculated as week 4 minus baseline and week
8 minus baseline. Continuous variables were analysed using a
two sample t test or Wilcoxon rank sum test, as appropriate.
Categorical variables were analysed using a x2 test or Fisher’s
exact test, as appropriate. Post hoc within group analyses
were conducted to examine changes from baseline to week 4
and 8 using the paired t test or Wilcoxon signed rank test, as
appropriate. Correlation product moment analyses were
performed, within groups, on a subset of the data variables.
The relationship of supplement consumption, plasma EPA,
and dietary intake with the study end points was assessed for
the two groups using analysis of covariance and also
separately for the experimental and control groups using
the Pearson correlation coefficient. The Wilcoxon signed rank
test was used to examine whether there was a relationship
between the amount of experimental product consumed and
specific outcomes. Patient survival was estimated from the
date of study enrolment by the Kaplan-Meier method. All
results were considered to be statistically significant if the p
value was less than 0.05.
RESULTS
A total of 200 weight losing patients (95E and 105C) with
unresectable pancreatic cancer were enrolled and randomised
in the study. Patient characteristics at enrolment and
baseline are shown in table 1. The two groups were
comparable for all variables (p.0.05). However, there was
a trend towards a greater proportion of stage IV disease
patients in the experimental group (52%) than in the control
group (41%). At baseline, patients had been losing approxi-
mately 3.3 kg/month (2.2 kg of which was estimated to be
LBM) and had lost 17% of their pre-illness stable weight.
Approximately one third of patients in each group (32% E,
28% C) were using pancreatic enzyme supplements for the
treatment of steatorrhoea/malabsorption at the start of the
study. Patients were well matched for Karnofsky perfor-
mance score and quality of life characteristics (table 1). In
general, the values reflect a debilitated older group of patients
with significant impairment of physical function and global
health status.
Fifteen patients withdrew between enrolment and base-
line. Thus 185 patients (88E and 97C) were assessed at
baseline. Thereafter, 148 patients were assessed at four weeks
(70E and 78C) and 110 at eight weeks (50E and 60C) (fig 1).
The reasons for sample attrition between enrolment and the
end of the eight week study period are also shown in fig 1.
Both the experimental and control oral supplements were
well tolerated. There were no significant differences in the
number of patients who experienced adverse events or
serious adverse events between the experimental and control
groups. None of the serious adverse events were considered
to be due to the oral supplements. Rather, the investigators
concluded that they were due to disease progression.
Table 1 Enrolment and baseline characteristics of 200 weight losing patients with
unresectable pancreatic cancer
Experimental group
(n = 95)
Control group
(n = 105)
Enrolment characteristics
Sex (M:F) 54:41 56:49
Age (y) 67 (1) 68 (1)
Histological proof of diagnosis 55 (58%) 61 (58%)
Stage of disease
II 31 (33%) 40 (39%)
III 14 (15%) 21 (20%)
IV 49 (52%) 42 (41%)
Usual weight (kg) 72.7 (1.2) 74.7 (1.4)
Pancreatic enzyme
supplementation
30 (32%) 29 (28%)
Baseline characteristics (0 weeks) Experimental Control
Weight at baseline (kg) 60.3 (1.1) (n = 88) 61.4 (1.2) (n = 97)
Duration of weight loss (weeks) 26.0 (2.1) (n = 88) 25.3 (2.0) (n = 96)
Rate of weight loss (kg/4 weeks) 2.9 (0.2) (n = 88) 3.2 (0.3) (n = 96)
% weight loss from usual weight 17.9 (0.9) (n = 88) 17.1 (0.8) (n = 97)
Body mass index (kg/m2) 21.8 (0.4) (n = 88) 22.0 (0.4) (n = 97)
Lean body mass (kg) 43.3 (0.9) (n = 80) 43.4 (0.9) (n = 91)
Karnofsky performance score 74.9 (1.2) (n = 88) 73.9 (1.0) (n = 98)
EQ-5Dindex 0.62 (0.03) (n = 86) 0.62 (0.03) (n = 91)
EQ-5Dvas 52.3 (2.2) (n = 87) 57.2 (1.9) (n = 96)
EORTC QLQ-C30 global HS 48.8 (2.2) (n = 86) 53.1 (2.2) (n = 95)
EORTC QLQ-C30 physical function 64.1 (2.2) (n = 87) 67.7 (2.3) (n = 96)
Meal intake (kcal/day) 1504 (54) (n = 84) 1613 (51) (n = 95)
Meal intake (g protein/day) 60 (2) (n = 84) 63 (2) (n = 95)
Values are mean (SEM) or percentage of group (%).
HS, health score.
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The recommended supplement dose was 2 cans/day.
However, intake of the supplements (E or C) averaged 1.4
cans/day. Oral supplement consumption and dietary intake
(completed by 100/110 patients at eight weeks) are shown in
table 2. There was no significant difference between the
groups for supplement intake (p = 0.63) or for change in
meal (p = 0.24) or total dietary intake (p = 0.16) over the
eight week period. However, there was a significant increase
in total (meals plus supplement) dietary intake from baseline
for those patients in the experimental group completing eight
weeks (15 g protein/day (p,0.001) and 224 kcal/day
(p = 0.001)). In contrast, total protein intake increased
significantly but there was only a trend towards an increase
in total energy intake for those patients completing eight
weeks in the control group (6 g protein/day (p = 0.036) and
68 kcal/day (p = 0.098)).
Based on plasma phospholipid EPA levels, there was
evidence of deviation from protocol in both the control and
experimental groups. There were patients in both groups with
high levels of EPA at baseline (14%), suggesting possible
undisclosed prior supplementation with n-3 fatty acids. In
addition, 18% of control patients had high EPA levels at
weeks 4 and/or 8. Conversely, 26% of experimental patients
had reported at least some intake of the experimental
supplement but had little or no elevation of EPA (that is,
(1.6%) in plasma at either week 4 or 8.
Observed changes in weight and LBM after four and eight
weeks of oral supplementation are shown in figs 2 and 3.
Over the eight week study period, weight (D weight E:
20.25 kg/month versus C: 20.37 kg/month) and LBM
(D LBM E: +0.27 kg/month versus C: +0.12 kg/month) were
stable and not significantly different between groups
(p = 0.74, p = 0.88, respectively). When compared with rates
of loss at baseline, there was a significant attenuation of
weight and LBM loss in both study groups at four and eight
weeks (p,0.001 for all within group comparisons). There
were no significant differences in prestudy rates of loss of
weight or LBM between patients who did or did not complete
the eight week study period. With respect to other indices
over the trial period, there were no significant differences
between groups in performance scores or any of the quality of
life measures (data not shown).
In view of the relatively low mean levels of compliance,
correlation analyses were undertaken to examine for poten-
tial dose-response relationships in either group (E or C) over
the eight week study period. There was a significant positive
correlation in the experimental group between daily supple-
ment intake and increases in both body weight (r = 0.50,
p,0.001) (fig 4A) and LBM (r = 0.33, p = 0.036) (fig 4C). In
contrast, there were no such correlations in the control group
(fig 4B, 4D). A comparison of the relationships between
supplement intake and change in weight or LBM in the
experimental group versus the control group suggested the
correlations to be marginally different for weight (p = 0.053)
and significantly different for lean body mass (p = 0.043). In
the experimental group, maximal gain in weight and LBM
was observed with an intake of 1.5–2 cans per day (fig 5).
Moreover, there was a significant positive correlation
between week 8 plasma EPA and increases in weight
(r = 0.50; p,0.001) and LBM (r = 0.51, p = 0.001) (fig 6) in
the experimental group.
Although there were no significant differences in quality of
life measures between the two groups, the intake of the
experimental supplement correlated positively with quality of
life as measured by EQ5Dindex (r = 0.37, p = 0.01) while the
intake of control supplement showed no such correlation
(r = 0.04, p = 0.77). There was a trend suggesting these
relationships to be significantly different (p = 0.082). Weight
gain in the experimental group correlated significantly with
EQ5Dindex (r = 0.46, p,0.001). There was no such statistically
significant correlation (p = 0.59) observed within the control
group. Covariate analysis confirmed these relationships to be
significantly different (p = 0.038).
Allocated to
control group
n=105
Randomised
n=200
Allocated to
experimental group
n=95
Lost to
follow up
n=45
Lost to
follow up
n=45
Enrolment
n=97
n=11 (1+5+5)Death n=16 (0+8+8)
n=15 (7+2+6)
Patient and/or family
withdrawal
n=11 (6+2+3)
n=17 (0+11+6)Change in medical
status
n=16 (1+7+8)
n=1 (0+1+0)Adverse event n=1 (0+1+0)
n=1 (0+0+1)Use of steroids n=1 (0+0+1)
n=88
n=78 n=70
n=60
Baseline
Week 4
Week 8 n=50
Figure 1 Patient disposition. Number of patients lost to follow up
(enrolment to baseline+baseline to week 4+week 4 to week 8).
Table 2 Oral nutritional supplement intake and change in meal intake and total dietary
intake for the experimental and control groups over the eight week study period
Experimental Control
Supplement intake (cans/day) 1.44 (0.1) (n = 44) 1.43 (0.06) (n = 56)a
Supplement intake (kcal/day) 448 (23) (n = 44) 444 (19) (n = 56)a
Supplement intake (g pro/day) 23 (1.2) (n = 44) 23 (1.0) (n = 56)a
Meal intake (kcal/day) 2223 (63) (n = 44)c 2376 (65) (n = 56)a c
Meal intake (g protein/day) 28 (3.2) (n = 44)b 217 (3.2) (n = 56)a c
Total intake (kcal/day) 224 (68) (n = 44)c 68 (64) (n = 56)a d
Total intake (g protein/day) 15 (3.5) (n = 44)c 6 (3.3) (n = 56)a b
aExperimental versus control, p = NS
Change from baseline to 8 weeks: bp(0.05, cp(0.001, dNS.
Values are mean (SEM).
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Median duration of survival from study enrolment for all
patients was 130 days and there was no significant difference
between the treatment groups (E: 142 (6–587) days; C: 128
(8–626) days (median (range)).
DISCUSSION
The present study has demonstrated no clear advantage at
the mean dose taken (1.4 cans/day) from enrichment of
specialised protein and energy dense oral supplements with
n-3 fatty acids in the treatment of patients with advanced
cancer cachexia. At baseline, patients had lost, on average,
17% of their pre-illness weight and were actively losing
weight at a rate of approximately 3.3 kg/month. Previous
studies of untreated patients have demonstrated a linear
pattern of continuous weight loss until near the time of death
in patients with unresectable pancreatic cancer.24 The present
study demonstrated that administration of specialised
protein and energy dense oral supplements (whether or not
enriched with n-3 fatty acids and antioxidants) was
associated with weight stabilisation which would tend to
suggest a net benefit from the use of such supplements in
this particular group of patients. However, due to the
advanced nature of their disease only 75% of patients reached
the four week end point and 55% of patients the eight week
end point. It could therefore be argued that the most severely
cachectic patients had either died or withdrawn by week 8
thus leaving patients who were more weight stable. However,
the baseline rate of weight loss was similar in patients who
did or did not reach week 8. This suggests that the observed
attenuation of cachexia was a genuine effect and not due to
selective attrition from either group.
At baseline, intakes of energy (1500–1600 kcal/day) and
protein (60–65 g/day) were insufficient to allow patients to
maintain body weight. The increased basal requirements of
cachectic cancer patients may have contributed to such an
imbalance. During the study, patients in both groups
consumed on average 1.4 cans of oral supplement per day
(equivalent to 420 kcal and 21 g protein/day). Although
spontaneous meal intake was partially reduced, the net gain
in total energy and protein intake appeared sufficient to
allow the patients in both groups to achieve overall weight
stability (fig 2). Previous trials of dietary advice and
conventional (1 kcal/ml) oral supplements in cancer patients
undergoing outpatient chemotherapy have suggested no
advantage compared with no dietary intervention.4 5
Overall, patients remained weight stable. However, in the
latter studies patients were at an earlier stage in disease, were
undergoing active anticancer treatment, and had not
sustained the degree of weight loss observed in the present
study. Clearly, however, in the absence of an untreated
control group in the present trial it is not possible to assess
definitely the efficacy of energy and protein dense oral
supplements in advanced cancer cachexia.
The experimental supplement used in this study was
designed to deliver a pharmacological dose of n-3 fatty acids
within a nutrient matrix to provide extra protein and energy
and allow net deposition of lean tissue. However, by incor-
porating the EPA in a nutritional supplement, the dose of
EPA was then linked to overall supplement intake. Previous
studies in cachectic pancreatic cancer patients suggested that
EPA alone at a dose of 2 g/day was associated with weight
stability10 and that when incorporated in a nutrient matrix
as used in the present study, a dose of 2.1 g/day (from
consumption of 1.9 cans/day) was associated with net gain of
lean body mass.15 Average can consumption in the present
trial was 1.4 cans/day (containing 1.5 g EPA). Although
arrest of further loss of both weight and lean tissue was
observed, at this mean level of intake there was no net gain of
lean body mass and no advantage for the supplement
enriched with n-3 fatty acids and antioxidants when
compared with the control supplement. It therefore remains
to be tested whether if compliance can be improved (such
that a net dosed EPA of 2 g/day is administered) there would
be an advantage for n-3 enriched energy and protein dense
oral supplements in terms of achieving net anabolism.
One explanation for the difference in compliance between
the pilot study15 (average intake 1.9 cans/day) and the
present randomised controlled trial (average 1.4 cans/day)
would be different levels of patient motivation for supple-
ment consumption based on the patient’s perception of
potential benefit in the context of a single arm study versus a
randomised trial. Further studies focused on methods of
optimising compliance (for example, patient information
sheets) both within and outwith the context of randomised
studies would be useful. Moreover, although compliance
could be checked for the experimental supplement using
plasma EPA levels, it would be useful for further studies to
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cancer cachexia. *NS (p = 0.49) at baseline, 0.95 at four weeks, and
0.74 at eight weeks between groups; **p,0.001 within group
comparisons to baseline.
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Figure 3 Effect of protein and calorie dense oral supplements, with or
without n-3 fatty acids, on change in lean body mass in patients with
pancreatic cancer cachexia. *NS (p = 0.85) at baseline, 0.95 at four
weeks, and 0.88 at eight weeks between groups; **p,0.001 within
group comparisons to baseline.
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have a tracer (for example, deuterated water) in both the
control and experimental oral supplements.
In the present study, patients had been stratified for centre
and histological proof of diagnosis, but not for stage of
disease. Baseline characteristics revealed that there were
more stage IV patients randomised to the experimental
group. Although not statistically significant, this could have
influenced the results observed with group comparisons as
patients with more advanced disease might be less able to
take in normal food, and consume and respond to the
intervention. In addition, the combined effect of some
patients in both groups failing to declare n-3 fatty acid
supplement use at baseline and some patients in the control
group supplementing themselves with an alternative source
of n-3 fatty acids during the trial may have further dampened
any treatment differences that could have been observed
between groups.
In order to test whether there was a dose-effect relation-
ship within the present study, a post hoc series of correlation
analyses based on the ITT population was undertaken. These
analyses demonstrated a significant positive correlation
between intake of the supplement and gain in either body
weight or LBM in the group receiving the experimental
product (fig 4A, C). There was however no such relationship
in the control group (fig 4B, D). Moreover, the relationship
between supplement intake and change in LBM was
significantly different between the experimental and control
groups. A further observation supporting a dose-response
relationship in the present study is that in those randomised
to the experimental group, there was a significant positive
correlation between week 8 plasma phospholipid EPA levels
and an increase in body weight. Plasma phospholipid EPA
levels also correlated strongly with changes in LBM (fig 6).
Clearly, however, not all the change in LBM can be ascribed
to changes in plasma EPA levels. Other modulating factors
may include changes in the level of intake of other nutrients,
changes in the level of physical activity of the patients, or
genetically determined variation in the response to EPA.25
The aim of nutritional and metabolic support in cancer
cachexia is not only to restore normal body composition but
also to improve function and quality of life. Previous studies
using the appetite stimulant medroxyprogesterone acetate
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have demonstrated significant attenuation of weight loss in
cachectic cancer patients.26 However, this did not translate
into an improved quality of life (as assessed by the EORTC
QLQ C-30). One explanation was that the main tissue
preserved was fat rather than lean body mass. In the present
study, LBM of patients who took the experimental supple-
ment at the recommended dose (1.5–2 cans/day) increased
(fig 5) and the intake of the experimental supplement was
correlated positively with improved LBM and EQ-5Dindex.
This potential relationship between LBM and quality of life is
worthy of further study in patients with cancer cachexia.
Previous studies both in vitro and in vivo have suggested
that n-3 fatty acids may have potential as antineoplastic
therapy. Tumour response was not evaluated in the present
study. However, there was no difference in the survival
duration between control and experimental arms. The
median survival of all patients from the time of enrolment
was 130 days which is similar to that reported in recent
randomised trials of chemotherapy or novel antineoplastic
agents.27 28
In summary, due to a variety of compliance issues, the
present trial failed to address the hypothesis developed from
the pilot data.15 Further development of nutraceutical trial
design is required to overcome these issues and address the
potential efficacy of n-3 fatty acid enrichment of oral
supplements in cancer cachexia. The issue of whether energy
and protein dense oral supplements are of specific value is
also worthy of further evaluation.
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